The Role of Setmelanotide In Improving Hypercapnic Chemosensitivity and Weight Loss In Male Mice

Obesity is a significant contributor to respiratory disorders such as Obesity Hypoventilation Syndrome (OHS) and sleep apnea, both of which are characterized by reduced respiratory chemosensitivity. These conditions not only impair breathing but also exacerbate the health risks associated with obesity. Recent research from Rivera (2024) investigates the potential of setmelanotide, a melanocortin-4 receptor (MC4R) agonist, to address these issues by improving hypercapnic ventilatory response (HCVR) alongside promoting weight loss.